1443.2: A Phase 1, open-label study of SIRPα antagonist (BI 765063) in combination with ezabenlimab (PD-1 inhibitor) alone or with (BI 836880) VEGF/ANG2, chemotherapy or cetuximab in patients with recurrent/metastatic HNSCC or HCC^1,2

Zoom

1. NCT05249426. https://clinicaltrials.gov/ct2/show/study/NCT05249426. Accessed September 2023; 2. Boehringer Ingelheim. Data on file.